Resolving the atomic level activation mechanisms of lecithin-cholesterol acyltransferase-targeted therapeutic agents utilising a novel combination of modern computational and experimental techniques

Description of the granted funding

Lecithin-cholesterol acyltransferase (LCAT) is one of the key enzymes in the metabolism of high-density lipoproteins (HDLs). This research project resolves the unclear activation mechanism of LCAT enzyme by utilizing therapeutic HDL-mimicking nanodiscs and small positive allosteric modulators. The study combines in a new way the state-of-the-art computational and experimental methods to achieve an atomistic description of how LCAT enzyme interacts with its activating HDL-mimetic nanodiscs and positive allosteric modulators, and how these therapeutics mechanistically activate LCAT. In addition, the mechanistic insights acquired during the project will be translated to more potent in vivo properties. The results contribute to the development of new therapeutic agents against dyslipidemic conditions. In addition, it provides a new computational and experimental platform for studying the structure and function of therapeutic nanodiscs in different contexts.
Show more

Starting year

2022

End year

2027

Granted funding

Artturi Koivuniemi Orcid -palvelun logo
447 650 €

Related funding decisions

372121
Research costs of Academy Research Fellows(2025)
200 000 €
353815
Research costs of Academy Research Fellows(2022)
300 000 €

Funder

Research Council of Finland

Funding instrument

Academy research fellows

Decision maker

Scientific Council for Biosciences, Health and the Environment
30.05.2022

Other information

Funding decision number

350636

Fields of science

Pharmacy

Research fields

Farmasia

Identified topics

pharmacy, biomedicine